To the top

Page Manager: Webmaster
Last update: 9/11/2012 3:13 PM

Tell a friend about this page
Print version

Polygenic dissection of d… - University of Gothenburg, Sweden Till startsida
Sitemap
To content Read more about how we use cookies on gu.se

Contact form








 


Note! If you want an answer on a question you must specify your email address




Polygenic dissection of diagnosis and clinical dimensions of bipolar disorder and schizophrenia.

Journal article
Authors D M Ruderfer
A H Fanous
S Ripke
A McQuillin
R L Amdur
P V Gejman
M C O'Donovan
O A Andreassen
S Djurovic
C M Hultman
J R Kelsoe
S Jamain
Mikael Landén
M Leboyer
V Nimgaonkar
J Nurnberger
J W Smoller
N Craddock
A Corvin
P F Sullivan
P Holmans
P Sklar
K S Kendler
Published in Molecular psychiatry
Volume 19
Issue 9
Pages 1017–1024
ISSN 1476-5578
Publication year 2014
Published at Institute of Neuroscience and Physiology
Pages 1017–1024
Language en
Links dx.doi.org/10.1038/mp.2013.138
Keywords bipolar; clinical symptoms; cross disorder; polygenic; schizophrenia
Subject categories Neuroscience, Medical Genetics, Psychiatry

Abstract

Bipolar disorder and schizophrenia are two often severe disorders with high heritabilities. Recent studies have demonstrated a large overlap of genetic risk loci between these disorders but diagnostic and molecular distinctions still remain. Here, we perform a combined genome-wide association study (GWAS) of 19 779 bipolar disorder (BP) and schizophrenia (SCZ) cases versus 19 423 controls, in addition to a direct comparison GWAS of 7129 SCZ cases versus 9252 BP cases. In our case-control analysis, we identify five previously identified regions reaching genome-wide significance (CACNA1C, IFI44L, MHC, TRANK1 and MAD1L1) and a novel locus near PIK3C2A. We create a polygenic risk score that is significantly different between BP and SCZ and show a significant correlation between a BP polygenic risk score and the clinical dimension of mania in SCZ patients. Our results indicate that first, combining diseases with similar genetic risk profiles improves power to detect shared risk loci and second, that future direct comparisons of BP and SCZ are likely to identify loci with significant differential effects. Identifying these loci should aid in the fundamental understanding of how these diseases differ biologically. These findings also indicate that combining clinical symptom dimensions and polygenic signatures could provide additional information that may someday be used clinically.Molecular Psychiatry advance online publication, 26 November 2013;

Page Manager: Webmaster|Last update: 9/11/2012
Share:

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?